Latest News

Are trial data generalizable to MS population?


An analysis of patients in the German MS Register has found that 83% of real-world patients would not have met inclusion/exclusion criteria for entry in a trial of disease-modifying therapies (Jalusic et al. Mult Scler 2021; epublished January 20, 2021). Read More


Few vaccine responders with fingolimod, ocrelizumab


Most MS patients currently treated with fingolimod or ocrelizumab will fail to mount an immune response to COVID-19 vaccination, according to the results of the first real-world study of vaccine response in MS patients on disease-modifying therapies (DMT) (Achiron et al. Ther Adv Neurol Disord 2021:14:1-8). An adequate vaccine response was seen in cladribine-treated patients. Read More